Residual tumor volume and patient survival following reoperation for recurrent glioblastoma

Journal of Neurosurgery

Volumn 121, Issue 4, 2014, Pages 802-809

  Yong, Raymund L ^a   Wu, Tianxia ^b   Mihatov, Nino ^a   Shen, Michael J ^a   Brown, M Anthony ^a   Zaghloul, Kareem A ^a   Park, Grace E ^a   Park, John K ^c  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^b NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

^c Department of Pharmacy Services   (United States)

Author keywords

Glioblastoma; Oncology; Recurrent tumor; Reoperation; Survival

Indexed keywords

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CLINICAL TRIAL; FEMALE; GLIOBLASTOMA; GROUPS BY AGE; HUMAN; KPS SCORE; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MINIMAL RESIDUAL DISEASE; NEURORADIOLOGY; NEUROSURGERY; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; OVERALL SURVIVAL; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; PROSPECTIVE STUDY; REOPERATION; SCORING SYSTEM; SURVIVAL RATE; SURVIVAL TIME; TUMOR GROWTH; TUMOR RECURRENCE; TUMOR VOLUME; BRAIN NEOPLASMS; MIDDLE AGED; MORTALITY; NEOPLASM RECURRENCE, LOCAL; PATHOLOGY; YOUNG ADULT;

ADULT; AGED; BRAIN NEOPLASMS; FEMALE; GLIOBLASTOMA; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM, RESIDUAL; PROSPECTIVE STUDIES; REOPERATION; SURVIVAL RATE; TUMOR BURDEN; YOUNG ADULT;

EID: 84907879383     PISSN: 00223085     EISSN: 19330693     Source Type: Journal    
DOI: 10.3171/2014.6.JNS132038     Document Type: Article

References (13)

1. Allison PD: Survival Analysis Using SAS: A Practical Guide, ed 2. Cary, NC: SAS Institute, 2010
2. Ballman KV, Buckner JC, Brown PD, Giannini C, Flynn PJ, LaPlant BR, et al: The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme. Neuro Oncol 9: 29-38, 2007
3. Brandes AA, Bartolotti M, Franceschi E: Second surgery for recurrent glioblastoma: Advantages and pitfalls. Expert Rev Anticancer Ther 13: 583-587, 2013
4. Cankovic M, Nikiforova MN, Snuderl M, Adesina AM, Lindeman N, Wen PY, et al: The role of MGMT testing in clinical practice: A report of the association for molecular pathology. J Mol Diagn 15: 539-555, 2013
5. Gorlia T, Stupp R, Brandes AA, Rampling RR, Fumoleau P, Dittrich C, et al: New prognostic factors and calculators for outcome prediction in patients with recurrent glioblastoma: A pooled analysis of EORTC Brain Tumour Group phase I and II clinical trials. Eur J Cancer 48: 1176-1184, 2012
6. Grossman SA, Ye X, Piantadosi S, Desideri S, Nabors LB, Rosenfeld M, et al: Survival of patients with newly diagnosed glioblastoma treated with radiation and temozolomide in research studies in the United States. Clin Cancer Res 16: 2443-2449, 2010
7. Lacroix M, Abi-Said D, Fourney DR, Gokaslan ZL, Shi W, DeMonte F, et al: A multivariate analysis of 416 patients with glioblastoma multiforme: Prognosis, extent of resection, and survival. J Neurosurg 95: 190-198, 2001
8. Park JK, Hodges T, Arko L, Shen M, Dello Iacono D, McNabb A, et al: Scale to predict survival after surgery for recurrent glioblastoma multiforme. J Clin Oncol 28: 3838-3843, 2010
9. Sadones J, Michotte A, Veld P, Chaskis C, Sciot R, Menten J, et al: MGMT promoter hypermethylation correlates with a survival benefit from temozolomide in patients with recurrent anaplastic astrocytoma but not glioblastoma. Eur J Cancer 45: 146-153, 2009
10. Sanai N, Polley MY, McDermott MW, Parsa AT, Berger MS: An extent of resection threshold for newly diagnosed glioblastomas. Clinical article. J Neurosurg 115: 3-8, 2011
11. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352: 987-996, 2005
12. Weller M, Cloughesy T, Perry JR, Wick W: Standards of care for treatment of recurrent glioblastoma-Are we there yet? Neuro Oncol 15: 4-27, 2013
13. Weller M, Stupp R, Reifenberger G, Brandes AA, van den Bent MJ, Wick W, et al: MGMT promoter methylation in malignant gliomas: Ready for personalized medicine? Nat Rev Neurol 6: 39-51, 2010